Compass Therapeutics: Good Execution, Major Catalysts Ahead
Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...
Compass Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target Discover the Best Stocks and Maximize Your ...
Yahoo Finance26d
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its pipeline development programs and current cash position. The phenomenal ...
Compass stock gains amid Guggenheim buy rating
Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...
ETF Daily News6d
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Piper Sandler
Shares of Compass Therapeutics stock opened at $3.38 on Wednesday. The firm has a market cap of $465.05 million, a P/E ratio of -9.13 and a beta of 1.17. Compass Therapeutics has a 12 month low of ...
Yahoo Finance28d
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s ...